Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9295951 | 0.65 | MEN1 (0.45) | ALDH1A1MEN1LMNATP53PKM | |
| SCHEMBL691164 | 0.59 | — | — | |
| SCHEMBL18287198 | 0.58 | POLB (0.40) | SMN1; SMN2GAA | |
| SCHEMBL11476478 | 0.55 | GRM5 (0.43) | ALDH1A1MEN1LMNATP53PKM | |
| SCHEMBL13748501 | 0.55 | MAPT (0.47) | ALDH1A1LMNAMAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL626926 | 0.55 | — | — | |
| SCHEMBL11459994 | 0.54 | INMT (0.46) | ALDH1A1MEN1LMNAMAPK1KMT2A | |
| SCHEMBL11460318 | 0.54 | GRM5 (0.45) | ALDH1A1MEN1LMNATP53PKM | |
| SCHEMBL11460317 | 0.54 | GRM5 (0.45) | ALDH1A1MEN1LMNATP53PKM | |
| SCHEMBL7215120 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666577-B2 | MLKL inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-06-06 | — | — | US | disclosed |
| US-11666577-B2 | MLKL inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666577-B2 | MLKL inhibitors | MLKL, CMKLR1, PCSK9 | ALDH1A1 4376/4885MEN1 129/4885LMNA 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.